{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:17:13Z","timestamp":1788333433471,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20251552"],"award-info":[{"award-number":["20251552"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Acute ischemic stroke remains a major cause of death and disability, and intravenous thrombolysis is central to early reperfusion; however, post-lysis thrombin activity may contribute to rethrombosis and incomplete reperfusion. We conducted a single-center retrospective cohort study of consecutive adults with acute ischemic stroke admitted between January 2023 and December 2024, comparing a control regimen of standard-dose recombinant tissue plasminogen activator (alteplase 0.9\u2009mg\/kg, maximum 90\u2009mg) with an observation regimen of low-dose recombinant tissue plasminogen activator (0.6\u2009mg\/kg, maximum 60\u2009mg) plus argatroban initiated after thrombolysis in clinically stable patients. Because treatment strategy was selected in routine care rather than randomly assigned, all comparative findings were interpreted as associations. Among 125 patients (control n\u2005=\u200567; observation n\u2005=\u200558) with comparable baseline characteristics, the observation regimen was associated with greater early neurological improvement on the National Institutes of Health Stroke Scale at 24 hours (median change, 4 vs 3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001) and day 7 (6 vs 4;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001), with higher responder rates (National Institutes of Health Stroke Scale decrease \u22654) at 24 hours (67.2% vs 41.8%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.004) and day 7 (81.0% vs 59.7%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.010). Favorable 90-day functional outcomes on the modified Rankin Scale (mRS) were more frequent (mRS 0\u20131: 69.0% vs 47.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.017; mRS 0\u20132: 87.9% vs 70.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.016), with a more favorable ordinal mRS distribution (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001). Recanalization was more frequent (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.028), infarct growth was lower (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001), and early neurological deterioration was less common (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.037). Symptomatic intracranial hemorrhage and other adverse events were uncommon, without significant between-group differences. These real-world findings should be considered hypothesis-generating and require prospective randomized validation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049809","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:02:18Z","timestamp":1784322138000},"page":"e49809","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Shaoyue","family":"Huang","sequence":"first","affiliation":[{"name":"The Second Department of Cerebrovascular Disease, Cangzhou Central Hospital, Cangzhou City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Department of Cerebrovascular Disease, Cangzhou Central Hospital, Cangzhou City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Department of Cerebrovascular Disease, Cangzhou Central Hospital, Cangzhou City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Neurophysiology, Cangzhou Central Hospital, Cangzhou City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0728-8776","authenticated-orcid":false,"given":"Zhen","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurovascular Intervention, Cangzhou Central Hospital, Cangzhou City, Hebei Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"e076161","DOI":"10.1136\/bmj-2023-076161","article-title":"Advances in treatments for acute ischemic stroke.","volume":"389","author":"Sharma","year":"2025","journal-title":"BMJ"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000525822","article-title":"Treatments in ischemic stroke: current and future.","volume":"85","author":"Mosconi","year":"2022","journal-title":"Eur Neurol"},{"key":"R3-20260902","first-page":"e001824","article-title":"Food and Drug Administration approval of tenecteplase: what this means for the field of acute stroke treatment.","volume":"5","author":"Grotta","year":"2025","journal-title":"Stroke Vasc Interv Neurol"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","article-title":"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.","volume":"403","author":"Coutts","year":"2024","journal-title":"Lancet"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2402980","article-title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy.","volume":"391","author":"Xiong","year":"2024","journal-title":"N Engl J Med"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"1386386","DOI":"10.3389\/fneur.2024.1386386","article-title":"Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis.","volume":"15","author":"Yao","year":"2024","journal-title":"Front Neurol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/00185787241289296","article-title":"Improved door-to-needle time after implementation of tenecteplase as the preferred thrombolytic for acute ischemic stroke at a large community teaching hospital emergency department.","volume":"60","author":"Henderson","year":"2025","journal-title":"Hosp Pharm"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/jcm13020563","article-title":"Argatroban as an add-on to rtPA in acute ischemic stroke: a systematic review and meta-analysis.","volume":"13","author":"Chlorogiannis","year":"2024","journal-title":"J Clin Med"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"1364895","DOI":"10.3389\/fneur.2024.1364895","article-title":"Efficacy and safety of argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis.","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Neurol"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"e70799","DOI":"10.1002\/brb3.70799","article-title":"Timely initiation of argatroban improves prognosis in patients with acute ischemic stroke attributed to large artery atherosclerosis: a cohort study.","volume":"15","author":"Liu","year":"2025","journal-title":"Brain Behav"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2024.14721","article-title":"Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial.","volume":"332","author":"Meng","year":"2024","journal-title":"JAMA"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2023.7827","article-title":"Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial.","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/neurintsurg-2021-018589","article-title":"European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion.","volume":"14","author":"Turc","year":"2022","journal-title":"J Neurointerv Surg"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"e031692","DOI":"10.1161\/JAHA.123.031692","article-title":"Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke.","volume":"13","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jama.2023.0550","article-title":"Effect of argatroban plus intravenous alteplase vs intravenous alteplase alone on neurologic function in patients with acute ischemic stroke: the ARAIS randomized clinical trial.","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2314779","article-title":"Adjunctive intravenous argatroban or eptifibatide for ischemic stroke.","volume":"391","author":"Adeoye","year":"2024","journal-title":"N Engl J Med"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamaneurol.2023.5093","article-title":"Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial.","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:01:56Z","timestamp":1788332516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":18,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049809","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2025-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}